A Potential Protein Adjuvant Derived from Mycobacterium tuberculosis Rv0652 Enhances Dendritic Cells-Based Tumor Immunotherapy

Mycobacterium tuberculosis Rv0652 stimulates production of tumour necrosis factor and monocytes chemoattractant protein-1 in macrophages through the Toll-like receptor 4 pathway

(2012) Kwangwook Kim et al.   IMMUNOLOGY

Enhanced Efficacy of Therapeutic Cancer Vaccines Produced by Co-Treatment with Mycobacterium tuberculosis Heparin-Binding Hemagglutinin, a Novel TLR4 Agonist

(2011) I. D. Jung et al.   CANCER RESEARCH

Toll-Like Receptor Agonists

(2010) Sacha Gnjatic et al.   CANCER JOURNAL

Toll-Like Receptors: Cost or Benefit for Cancer?

(2010) T. Matijevic et al.   CURRENT PHARMACEUTICAL DESIGN

PE_PGRS Antigens of Mycobacterium tuberculosis Induce Maturation and Activation of Human Dendritic Cells

(2010) K. Bansal et al.   JOURNAL OF IMMUNOLOGY

Blockade of Indoleamine 2,3-Dioxygenase Protects Mice against Lipopolysaccharide-Induced Endotoxin Shock

(2009) I. D. Jung et al.   JOURNAL OF IMMUNOLOGY

The use of mycobacterial adjuvant-based agents for immunotherapy of cancer

(2008) J.M. Grange et al.   VACCINE